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All patients taking methotrexat e for treatment of pso-
riasis over the past 5 yr have been reviewed_ Thirty-
eight patients have had pretreatment liver biopsies and 
at lea st 1 r epeat liver biopsy. Of the 38, nine (24%) have 
developed s ignificant liver fibrosis or cirrhosis, and have 
stopped treatment. 
The high incidence of fibrosis is attributed to syner-
gism between methotrexate and other hepatotoxic fac-
tors, particularly alcohol, the u se of a baseline biopsy to 
identify subsequent changes, and the early detection of 
fibrosis by sensitive histological techniques. 
M ethotrexate provides dJ'ama tic a nd effective t reatmen t for 
psoriasis but has s ide effects, of which liver fibrosis progressing 
to cirrhosis is t he most importa n t. It is now recognized that a 
high-dose intermitten t regime is less likely to produce fibrosis 
than a low-dose continuous one [1-3] bu t t he incidence of and 
ris k factors influencing fibrosis a nd cirrhosis occurring on inter-
mittent therapy, either intramuscular or oral , are less cleal'ly 
defined. A v81'ying incidence of fibrosis in m e thotrexate-trea t ed 
psorias is, h as been reaOlted over the past 10 yr. Most of this 
evide nce comes from comparing differe nt groups, before and 
after commencem en t of treatment. Only r ar ely have patients 
been used as their own control as r ecommended by Roenigk et 
al [4] wi th pretr eatment biopsies to exclude s ignificant liver 
disease, foU owed by repeat liver biopsies at 1-2 ye81'ly intervals 
to assess t he e ffect of m ethotr exa te . Our experience over the 
pas t 5 years prospectively using such a r egin1e is presented . 
MATERIALS AND METHODS 
Patients 
All patients have been star ted on methotrexate because adequate 
control of their disease has not been possible with topical therapy. ALI 
patients except one had a pretreatment liver biopsy. All biopsies have 
been interpreted by one person (GHM-S). 
Methotrexate has been given by either the oral or intramuscul81' 
route in a single dose up to 30 mg weekly, for tnightly, or every 10 days. 
Follow-up with routine blood and platelet counts have been done every 
6-10 weeks. Liver function tes ts have not been performed routinely. 
M ethods 
The liver biopsies were performed by a right late ral technique under 
local anesthetic using a Klatskin or tru-cut needle. The biopsy was 
fIXed in 10% buffered formal in, processed by routine technique to 
paraffin blocks, and sections cut at 3-5 /-t . These have been rou tinely 
stained with hematoxylin and eosin, Perl 's Prussian Blue, periodic acid-
Schiff (PAS) after diastase diges tion, orcein, and Gordon 81ld Sweet 's 
reticulin wi thout gold toning or countersta ining. Those biopsie with 
fibrosis have been also stained by Van Gieson and a trichrome tech-
nique. Follow-up biopsies have been perfo rmed at 1-2 ye81'ly in tervals 
unless earlier biopsy was indicated. 
Biopsies were categorized as showing cUThosis, fibrosis of mild, 
moderate, or severe degree, nonspecific reactive change or fatty change. 
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Each biopsy was initially assessed blind . Further assessment of the 
follow-up biopsies included direct comp81'ison with the premethotrexate 
biopsy and other biopsies. Any increase in the demonstrable fib rous 
tissue was noted : details of past or current therapy were not known at 
the time of assessment. 
Fibrosis Was assessed by routinely used H & E, reticulin, and orcein 
preparations. Areas of fiber formation on the reticulin preparations can 
be subdivided into collagen (Type 1 collagen) staining brown, and 
reticulin (Type III) staining grey-black. Reticulin formation was con-
sidered to be less significant than collagen formation especia lly when 
focal and associated with granular , diastase- resistan t PAS-positive 
pigment within local macrophages. These indicate a recent episode of 
hepatocyte death and consequent collapse of the reticulin 81·chi tecture. 
In doubtful cases the orcein stain was of value as pre-existing "normal" 
collagen contains 181'ge irregular wavy elastic fibrils, mature "scar" 
collagen conta ins fine long, easily distinguished fib rils and both new 
collagen and reticulin collapse 81'e not stained. A semiquan titive grading 
of fibrosis into mild, moderate, and severe was used. When comp81'ed 
to the baseline biopsy an increase in mature collagen in the lobule or 
expanding te rminal portal tracts was considered either an indication 
for caution wi th early (6-12 mol rebiopsy, or fo r stopping methotrexate 
if the changes were more severe. Grade I was identified as foci of 
reticulin proliferation (Type 3 collagen) scatt.ered throughout the lob-
ules or occasionaJJy adjacent to and expanding portal tracts, Ul the 
absence of ceroid pigment in Kupffer cells. Grade II fibrosis showed 
more extensive enl81'gement of portal tracts by reticulin or the presence 
of mature collagen- wi th new orcein positive fibrils in the lobule or 
expanding pOJ;tal tracts. Linking of portal tracts usually with extension 
of fibrous spurs towards the central veins was interpreted as grade III. 
The one extreme of this grade overlapped wi th cirrhosis. 
The severi ty of the fatty change was graded on a ] -4 scale. Grade 1 
(0-25% hepatocytes containing fat) was considered to be P81·t of the 
nonspecific changes unless the affected cells showed a confluent zonal 
distribution. Other changes considered nonspecific were a scanty mono-
nuclear cell infiltra te in portal tracts, vacuolation of periportal hepa-
tocyte nuclei, and small focal necroses in the p81·enchyma. The latter 
were usually identified by the focal aggregation of lymphocytes and 
Kupffe r cells, and the presence of ceroid pigment in the diastase PAS 
prep81·ation. 
RESULT S 
Of the total group of 56 patien ts, e igh teen h ave not h ad 
follow-up biopsies. Thirty-seven patien ts have h ad both pre-
and posttreatmen t biopsies. Also included is one patien t wh o 
st81ted methotr exa t e before a biopsy was performed, bu t su b-
sequently h as h a d normal biopsies. T h e baseline liver biopsies 
all showed normal histology, mild nonspecific reactive ch a nges, 
or fatty ch a nge. Moder ate and more sever e degr ees of fibrosis 
wer e considered to be a n absolu te con traindication to stal·ting 
m ethot rexate, a nd h ence a ny patien t wi th this cha nge on t h e 
pretr ea tm en t biopsy has been excluded fr om th e series. Only 
one patien t wi th alcoholic liver disease was in fact excluded. 
Of the 38 p a tien ts th ere were 17 males, 21 females, of average 
age 53 yT ra nging o'om 29 to 81. Nine of th ese 38 patients (24%) 
have developed fibrosis a nd have stopped tr eatm en t (T a ble I) . 
One of t hese patie nts only ha d mild fi brosis after 2 Y.! y r of 
treatm ent . This alone wa not considered su ffic ient to stop 
m e thotrexate but as t he patient indicated a n unwillingn ess to 
have a regular liver biopsy, m ethou 'exate was with dra wn. Com -
parison of pa tien ts who ha ve developed fibr osis wi th t h ose who 
have no t, s how the aver age cumulative dose of t h e 9 patien ts 
230 ASHTON, MILLWARD-SADLER, AND WHITE 
with fibrosis to be 1955 mg of methotrexate over an average of 
28 mo, and for the 29 patients without fibrosis to be 1920 mg 
over 34 mo (Table II) . 
Twenty-five patients took the methotrexate orally, 7 by the 
intramuscular route, and 6 changed from oral to intramuscular 
route. Of the 9 patients developing fibrosis, 7 took the metho-
trexate orally, 1 intramuscularly, and 1 changed. 
Alcohol consumption has been graded as occasional (up to 3 
pints of beer or equivalent, <25 g alcohol per week), moderate 
(3-10 pints of beer per week or equivalent, 25-100 g/week), and 
heavy (more than 10 pints of beer or equivalent, > 100 g/week). 
Eight of the 38 patients were heavy drinkers, and 4 of these 
have developed fibrosis (Table I). A further one with fibrosis 
was a moderate drinker. 
Two patients developed cirrhosis, 2 severe fibrosis, 4 moder-
ate, and 1 mild fibrosis. Four of the 9 patients showed a 
histologically significant progression of fibrosis on repeated 
post-treatment biopsies. Of these 4 the only patient (P.V.) who 
developed cirrhosis had a regular moderate/heavy alcohol con-
sumption with Grade 2 centrilobular fatty change on the pre-
treatment and initial posttreatment biopsies (Fig. lA). The 
second posttreatment biopsy showed severe fibrosis with alco-
holic hepatitis (Fig. IB) and although methotrexate and alcohol 
were stopped, a further liver biopsy has demonstrated a quies-
cent micronodular cirrhosis (Fig. Ie). 
Of the remaining 5 patients, 2 showed moderate and 2 showed 
severe fibrosis on their first posttreatment biopsy. Two of these 
4 patients had regular moderate/heavy alcohol consumption 
and one (F.T.) who denied regular consumption of alcohol, had 
heterozygous alpha-I-antitrypsin (AIAT) deficiency. 
Three of the nine patients showed the classical features of 
alcoholic hepatitis: fatty change, ballooning degeneration of 
hepatocytes, Mallory bodies in hepatocytes, pericentral venous 
fibrosis and neutrophil inftltrates in the lobule, were seen in a 
posttreatment biopsy. Two of these patients admitted to regular 
alcohol consumption but one patient with AIAT deficiency 
denied alcohol and was supported in this assertion by her family 
and family doctor'. 
Although. the fibrosis in the biopsies showing alcoholic hep-
atitis was predominantly centrilobular with concomitant lesser 
involvement of portal tracts, in the other biopsies the fibrosis 
could be identified as small focal random scars in the lobule 
and short spurs irregularly expanding the edges of the portal 
tracts. In more severe degrees of fibrosis the spurs extended 
TABLE 1. Details of patients developing fibrosis 
Duration MTX dose (mg) 
Patient Agel Alcohol Route of sex trea tment Total Avl mo (mo) 
F .T ." 77 F 1 Oral 16 1060 66.2 
M .J . 56 F 3 0-IM 26 1300 50.0 
L.A. 66 F 1 Oral 31 1300 41.9 
A.L. 54 M 1 Oral 21 1367 65.1 
S.S. 66M 2 Ora l 36 1950 54.2 
P.V ." 54 F 3 Oral 38 2080 54 .7 
J.P. 56 M 3 Oral 30 2500 83.3 
V.S." 58 F 1 1M 26 2655 102.1 
T.G. 30M 3 Oral 30 3375 112.5 
" Case history and biopsy details illustrated. 
1 = < 25 g/ week;.2 = 25-100 g/week; 3 = > 100 g alcohol/week. 
TABLE II . Duration of treatment and cumulative dose of 
methotrexate at the time of latest liver biopsy 
Duration of Total MTX Av. 
Group No. trea tment dose (mg) dose per 
Av. Range Av. Range mo. 
Total 38 32.7 12-102 . 1928 800-5500 59.0 
Fibrosis 9 28.2 16- 38 1955 1060- 3375 69.3 
Nonfibrosis 29 34.0 12-102 1920 800-5500 56.5 
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from the portal tract a considerable way into the lobule and 
sometimes joined with a similar spur from the same or a 
different portal tract (Fig 2 A, B) . 
DISCUSSION 
From our study of 38 patients treated with methotrexate and 
having both pre- and posttreatment liver biopsies, 24% have 
developed fibrosis, necessitating the stopping of treatment. 
Comparisons with other series are difficult to make because the 
incidence of liver fibrosis in psoriasis treated with methotrexate 
has been assessed in 3 ways. Only one of these satisfactorily 
excludes pre-existing liver disease, Some studies compare the 
liver biopsies of psoriatics without previous exposure to meth-
otrexate, to those from a different group of patients who have 
had the drug. The incidence of fibrosis and cirrhosis in non-
methotrexate biopsies varies between 0-21% whereas in the 
methotrexate group the range is 6-54%. This higher incidence 
in the methotrexate group has been related to the average 
cumulative methotrexate dose [1,8,15]. Most of this evidence 
supporting cumulative dose toxicity is derived from series that 
employed an oral continuous low-dose therapy regime which 
has been clearly shown to have increased hepatotoxicity [2]. 
Our results agree with those other authors [4-6] who did not 
find any correlation with the cumulative dose of methotrexate. 
Other series follow posttreatment liver biopsies while the 
patient is receiving methotrexate but have not excluded pre-
existing liver disease. Variable results are seen in this group. 
Reece et al [7] found no fibrosis developing in 18 patients over 
27 mo, while Nyfors [5] found 19 of 68 with fibrosis or cirrhosis 
at the first follow-up biopsy, and 30 at the last biopsy. In Nyfors' 
series an average cumulative dose of methotrexate of almost 4 
g has been given by the last biopsy so that a cumulative dose 
toxicity after a "threshold" level is still a possibility. Further 
studies more accurately defining the average monthly dose of 
methotrexate in relation to mode and dciration of therapy and 
to body weight may clarify the issue. 
Thu'dly there are those series where posttreatment biopsies 
are compared with a pretreatment one from the same patient 
so that early changes can be detected (Table III). In doing this 
we have found a higher incidence (24%) of fibrosis than in other 
reported series with a similar protocol [8-10,12]. Although 
Almeyda et al [8] also found 22% with fibrosis this represented 
only 2 patients. Warin et al [10] found 1 case of fibrosis out of 
25 while Nyfors and Poulsen [12] found 11 (12.5%) of 88 patients 
developed cirrhosis or fibrosis . The average cumulative meth-
otrexate dose and average duration of treatment in both series 
is similar to ours and there was no statistically significant 
difference in the cumulative methotrexate dose between theu' 
patients with and without fibrosis/cirrhosis. A frequency of 
cirrhosis of 13.5% after 2 yr and 25.6% after 5 yr of methotrexate 
treatment has been noted [11]. These results are similar to ours 
and a similar average cumulative dose (2200 mg) was given 
although requiring 5 yr to achieve. 
A possible explanation for our finding of a high incidence of 
fibrosis could be that we used sensitive histological technique(s) 
routinely and identified lesser degrees of fibrosis. We have used 
two independent methods of detecting fibrosis [13]. Orcein 
demonstrates elastic fibrils, and distinguishes between pre-ex-
isting fibres in portal tracts, newly formed scar tissue and Type 
III collagen seen in the lobule as reticulin. Nongold-toned 
reticulin (Gordon and Sweet) differentiates between Type I 
collagen found in portal tracts and scar tissue and Type III 
collagen seen in the lobule as reticulin . 
Consequently scars can be separated from reticu lin collapse 
in the lobule. Many series use a trichrome stain to pick out 
fibrosis and we have therefore restained our slides by Van 
Giesen and trichrome techniques to see whether fibrosis is still 
detectable. The minor degrees of scar tissue are well demon-
strated by the reticulin preparations but scarcely visible on the 
trichrome and Van Giesen preparations. Severe degrees of 
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TABLE III. Incidence of fibrosis and cirrhosis developing in patients with both pre- and posttreatment liver biopsies 
Group No. Fibrosis Cirrhosis 
Av. length A.C.D." (mg) 
% of treatment 
Almeyda et ai, 1972 
Warin et ai, 1975 
Nyfors & Poulsen 1976 
This series 
8 
10 
12 
9 
25 
88 
36 
" A.C.D. = Average Cumulative Dose Methotrexate. 
1 
1 
5 
7 
(mo) 
1 22 23.4 
4 30 
6 12.5 26 
2 25 32.3 
FibI'. 
1291 
750 
2138 
1955 
'- I , 
• • 
, -
,. \ '" 
.•• ·IJ " 
... 
. . 
No fibI'. ToW 
697 829 
1802 1760 
1675 1733 
1935 1940 
.. 
. . 
eo-
-. 
FIG. 1. A , (P.V.) Premethotrexate liver biopsy showing a normal archi tecture with a portal tract (P) on the left and central vein (C) on the 
right. There is moderate fatty change in hepatocytes. High alcohol intake was subsequently confirmed on direct questioning. A second liver 
biopsy after 2 yr of methotrexate therapy was identical to this (reticulin x 250). B, The third biopsy after 2.08 g of methotrexate had been given 
over 38 mo shows pericentral fibrosis. Although fatty change is minimal there are ballooned hepatocytes containing Mallory bodies (arrows) and 
neutrophils are clustering in the sinusoids (H & E x 400) . C, The fourth liver biopsy 50 mo after struting therapy and 12 mo after methotr.exa~e 
was stopped shows a mic\'onodula\' cirrhosis. Severe fibrosis expands portal tracts, is ru'ound central veins and bridges these structures (retlculm 
X 400). 
fibrosis were easy to detect in all preparations. 
Our results do not show any relation between the incidence 
of fibrosis and cumulative methotrexate dose but other factors 
may influence the development offibrosis. Our group of patients 
with fibrosis contains a high proportion of "heavy" drinkers 
compal'ed to those not developing fibrosis and our findings 
support the relation to high alcohol intake already noted 
[9,12,14-16]. Although we have classified four of the patients as 
"heavy" consumers of alcohol, none of these patients had 
evidence of significant fibrosis on their initial biopsy and all 
denied any increase in alcohol consumption willie on metho-
trexate. Three of foW' "heavy" alcohol consumption patients 
showed Grade II centrilobular fatty change on their pretreat-
ment liver biopsies. At that time there was no fibrosis and the 
lesion was considered insignificant. Inasmuch as it may repre-
sent above average alcohol consumption we would recommend 
that the cause of zonal fatty change on a pretreatment biopsy 
is determined before MTX is given. In this respect we would 
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FIG 2. A, (V.S.) The fu'st follow-up liver biopsy after 1.87 g of 
methotrexate and 16 mo shows mild enlargement of a terminal portal 
tract by slender spms of fibrosis. A central vein is present bottom right 
(reticulin X 250) . B, The second follow-up biopsy after treatment with 
2.65 g of methotrexate over 28 mo shows djstortion of the architecture 
by new fibrous tissue in the lobule and expanding portal tracts (portal 
tracts P, central veins C) (reticulin X 100) . 
comment that the fatty change in the liver associated with 
psoriasis alone is usually focal in distribution and Grade I in 
severity. It is of note that one patient subsequently confIrmed 
serologically was found to have heterozygous alpha-I-antitryp-
sin defIciency on her pretreatment biopsy. She later developed 
severe changes identical to those found in alcoholic hepatitis 
and developed cirrhosis after very little methotrexate. Further 
questioning of the pa.tient and her family and her family doctor 
brought strong denial of alcohol excess. A second (referred and 
not in this series) similar patient's initial biopsy showed mild 
fibrosis; this has not progressed over 4 yr and after 1600 mg 
methotrexate but the last biopsy was 2 yr and 900 mg ago and 
a recent repeat biopsy was a technical failure. Another patient 
with a history of previous heavy alcohol intake has developed 
fIbrosis with increased iron deposition after methotrexate ther-
Vol. 79, No.4 
apy but the cause of this has not been identified. His serum 
ferritin is only marginally increased at 320 mg/ L. Family studies 
are in progress. We believe that it is probable that methotrexate 
acts synergistically with hepatotoxins and possibly accelerates 
liver diseases of other etiologies also. Consequently evidence of 
any pre-existing liver disease is a contraindication to metho-
trexate therapy as is persistent, even if not otherwise excessive, 
alcohol consumption. 
Our series is not large enough to determine whether there is 
any difference between intermittent oral or intramuscular 
routes in the development of fibrosis. The oral route is the most 
convenient and is usually used initially. The intramuscular 
route is used when side effects, usually gastrointestinal, occur. 
It would seem logical that the latter should be safer since it 
avoids the first pass through the liver in the portal vein, but 
retrospective studies [14] have failed to support this. 
Despite the high incidence of complications we feel that 
methotrexate remains a useful drug for the treatment of pso-
riasis if used with caution. Methotrexate should be used only: 
(a) If satisfactory control of psoriasis cannot otherwise be 
achieved. (b) In the absence of other hepatotoxic factors or any 
regular alcohol intake. (c) If a pretreatment biopsy does not 
show any pre-existing liver disease. (d) If follow-up liver biop-
sies do not contra-indicate further therapy. 
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